Pages
- Become a Site Champion
- Becoming a client
- Blog
- Canadian Investigators
- Cancer Patients
- Careers
- Contact Us
- Events & Conferences
- Home
- Newsroom
- Oncology Experience
- Our Company
- Our Team
- Phase 3 Oncology Clinical Trial Expertise
- Podcasts
- Privacy Policy
- Resource Library
- Reverse Feasibility Champions Award
- Reverse Feasibility Program
- Sitemap
- Small & Mid-Sized Biopharma
- Thanks you !
Posts by category
- Category: Accelerated Site Start-Up
- 25 Years of Unparalleled Canadian Oncology Clinical Research Experience
- Assessing the Canadian Landscape for Cancer Research
- eTMF Best Practice for a Lean Team
- Recovering a Derailed Clinical Trial – Best Practices
- What’s Best for Your Phase III Clinical Study?
- Special Report: What’s in Store for Global Clinical Trials in 2022 and Beyond?
- Why Not Canada for Your Phase 3 Global Trial Expansion?
- Diversity in Clinical Trial Participants: Canada Holds Promise
- 2020 a Year Like No Other: What it Takes to Keep Ahead of Rapid Change
- Overcome Oncology Clinical Trial Obstacles – 2020 Real World Evidence for 2021 and Beyond
- Some Facts About Canada… Mitigate COVID-19 Impact on Your Clinical Trials
- Smaller CROs May Do It Better, Quicker – Especially in Times of Crisis
- Consider This Region for Your Phase 3 Global Trial
- Recommendations for Quicker CTA Negotiation
- Overcome Today’s New Enrollment Challenges
- Collaborative Vendor Teaming for Better Oncology Trial Results – Real World Evidence
- Overcome Oncology Clinical Trial Obstacles – 2019 Real World Evidence for 2020 and Beyond
- Going Above-and-Beyond – What Can Your Specialized Oncology CRO Do for You?
- Oncology Trial Investigators and Participants – Where to Look?
- Hassle-Free Site Selection and Study Start-up for Clinical Trials in Canada
- Do You Believe the Myths About Conducting Clinical Trials in Canada?
- What is Most Important When Conducting Oncology Clinical Research in Canada?
- Your Specialized Oncology CRO as Strategic Advisor – Real World Evidence
- What to Look for When Selecting a CRO – Real World Evidence
- 2018 in Retrospect – Real World Evidence of Win-Win CRO/Sponsor Relationships
- 7 Tips for Efficient Oncology Study Start-up
- Real World Evidence of a Successful Oncology Trial Rescue in Canada
- How Does Your CRO’s Feasibility Process Contribute to Your Clinical Trial Success?
- Canadian Know-How: Successfully Navigating a Centralized Framework for Oncology Clinical Trial Ethical Review
- Canada: a Region of Choice for Your Study Expansion
- Why Does Your CRO’s Assignment Practice for CRAs Matter?
- Does Your Monitoring Vendor Hold the Key to Improving the Quality of Your Database?
- Will Canada’s Multi-Center Approval Processes Help Your Oncology Clinical Trial Exceed Pivotal Milestones?
- Exploring a ‘Rescue’ Strategy for Your Oncology Clinical Trial?
- Effectively Integrating a Regionally Specialized CRO Team into Your Existing US/Global Study Framework
- Navigating Canadian Regulations for Oncology Clinical Research – Part I
- ‘5 step’ fail proof strategy to effective Clinical Trial Agreement Negotiations part 2
- ‘5 step’ fail proof strategy to effective Clinical Trial Agreement Negotiations part 1
- Accelerate Start-up for Oncology Clinical Trials through Centralized Ethics Review
- Category: Centralized Ethics Review
- Category: COVID-19 Series
- Category: Earlier articles
- Centralized Ethics Review for Oncology Trials in Canada – An interview with Janet Manzo, Executive Director, Ontario Cancer Research Ethics Board
- Proven Approach to Site Selection is Attracting More Cutting-Edge Oncology Trials to Canada
- Impact of Clinical Trials on Cancer Patient Outcomes
- Leveraging Canada For Quicker Oncology Site Start-Up
- How to Start-Up 9 Oncology Sites in 9 weeks
- The Role of Patient Input for Oncology Drug Review – An Interview with CEO of the Canadian Cancer Action Network
- The Secret to Oncology Clinical Trial Performance – An Interview with Denise Deakin
- ‘Site’ vs. ‘Trial’ CRA assignments and why it matters
- Top 5 Questions asked by Directors of Clinical Operations
- Overcoming Site Challenges in Oncology Trials – An interview with Penny Chipman
- Reponse to Questions Raised Over Canadian Oversight Of Clinical Trials
- Oncology drug reimbursement climate in Canada
- Reverse Feasibility in Action – Transcript of interview with Dr. Quincy Chu
- Value of Canadian oncology centers for early phase trials – Transcript of interview with Dr. Stephen Welch
- Tips on developing oncology biomarkers and companion diagnostics – Transcript of interview with Dr. John Reddington
- How to get the most out of data warehousing and analytics – Transcript of interview with Steve Sweeney
- How to double your oncology enrolment targets
- How to speed up site start-up by 50%: Part 2 – Contract Negotiation
- Category: Early Phase Clinical Trials
- Let Canada Contribute to Your Basket Trial Success
- Do Data Entry Issues & Backlog Threaten Your Clinical Trial?
- How Do CRAs Proactively Manage Risk with These Soft Skills?
- Daffodils & Cancer Research – what’s the connection?
- Julie’s advice: Conducting oncology clinical research in Canada
- Clinical Trial Agreements no longer a bottleneck for study site activation
- Oncology Clinical Operations in Canada
- Busting Myths about the Canadian Regulatory Review Process – An interview with Susanne Picard
- Category: FAQs
- Category: General
- Category: Investigative Site Selection
- Category: Micro-patient Populations
- Category: Oncology Trials in Canada
- Canada: For Your Phase 3 Global Trial Expansion
- Troubleshooting Underperforming Sites – Best Practices
- Lessons Learned Moving Forward – Site Support & Remote Close Out
- Prime Location for Global Clinical Studies?
- What & Where: the ‘Next Normal’ in Oncology Clinical Research
- The Canadian Landscape for Childhood Cancer Research
- Scimega, Canada’s Premier CRO, Introduces Julie Martin, CEO
- CRAs Play a Supporting Role in Patient-Centric Trials
- The Role of Ethics from a Clinical Research Associate’s Perspective: Patient-Centered Research
- The Nearshoring Opportunity: Building a Solid Case for Oncology Studies in Canada
- Category: Patient Advocacy
- Category: Regulatory Affairs
- Category: Targeted Therapies
- Category: Technology in Clinical Trials
- Category: Uncategorized
Assets & Events
- 64th ASH Annual Meeting
- SITC 37th Annual Meeting
- 7th Meridian Clinical Trials Event
- How to Develop an Efficient TMF Management Process with a Lean Clinical Team
- Scimega introductory video
- Scimega Feasibility Expert shares valuable insights
- SCIMEGA CEO Julie Martin shares her experience
- Key Insight on the Importance of Low CRA Turnover from Scimega CEO, Julie Martin
- Phase Ib Antibody Drug Conjugate Study in Advanced Platinum-Resistant Ovarian Cancer
- Phase I/II Targeted Therapeutic Study in Advanced Colorectal Cancer
- Phase III Immuno-Oncology study in Advanced Renal Cell Carcinoma
- Phase I/II Advanced HER2+ Breast Cancer Study
- Reverse Feasibility in Action
- Expert Guidance to Key Advantages of Canadian Regulatory Landscape Scimega White Paper
- Clinical Cancer Advances Report
- Canadian Cancer Stats Report
- AACR Cancer Progress Report
- The Secret to Oncology Clinical Trial Performance
- Busting Myths about Canadian Regulatory Review
- Centralized Ethics Review for Oncology Trials in Canada
- Benefits of Big Data Analytics in Oncology Clinical Research
- Biomarkers & Companion Diagnostics in Oncology Clinical Research
- Quality, Speed & Performance – Key Attributes to Canada’s Oncology Clinical Trial Future
- Role of Patient Input for Oncology Drug Reviews
- A Word From Dr. Stephen Welch – A Reverse Feasibility Champion
- Optimizing North America For Your Oncology Trials
- Canadian Expansion from a Site’s Perspective
- The Reverse Feasibility Program Explained
- Value of Canadian Oncology Centers for Early Phase Trials